Sign in Subscribe
Cancer research

Enhancing Precision Medicine with Targeted RNA-Seq Detection

Strategic Insights

— 1 min read

Researchers at the U.S. Food and Drug Administration (FDA) have published a study highlighting the potential of targeted RNA-Seq detection in precision medicine. The team found that RNA-Seq can uniquely identify variants with significant pathological relevance missed by DNA-Seq, demonstrating its potential to uncover clinically actionable mutations. The study suggests that incorporating RNA-Seq into clinical biomarker panels will advance precision medicine and improve patient outcomes.

Key Takeaways:

  • The study focused on the integration of RNA sequencing (RNA-Seq) with DNA cancer mutation screening panels to assess the impact of variants on gene transcript expression and splicing.
  • Targeted RNA-Seq was used to detect expressed variants in a reference sample set, demonstrating its potential capability to complement DNA variant results or detect variants independently.
  • The results indicated that RNA-Seq uniquely identified variants with significant pathological relevance that were missed by DNA-Seq, with a carefully controlled false positive rate ensuring high accuracy.
  • Variants missed by RNA-Seq are often not expressed or expressed at very low levels, suggesting they may be of lower clinical relevance.
  • Incorporating RNA-Seq into clinical biomarker panels will ultimately advance precision medicine and improve patient outcomes by improving the strength and reliability of somatic mutation findings for clinical diagnosis, prognosis, and prediction of therapeutic efficacy.
  • The study's authors highlight the potential of RNA-Seq to bridge the "DNA to protein divide" and provide more clarity and therapeutic predictability for precision oncology.
  • The research was supported by the George Isaac Family Cancer Research Fund.

Statistics:

  • 9 out of 10 variants detected by RNA-Seq were found to have significant pathological relevance.
  • 12% of variants were detected by both DNA-Seq and RNA-Seq, while 20% were missed by one or the other.
  • RNA-Seq identified 35% more variants with significant pathological relevance when compared to DNA-Seq alone.

Sources:

  • Augmenting precision medicine via targeted RNA-Seq detection of expressed mutations. npj Precision Oncology, 2025,9(1):1-12. (npj Precision Oncology - https://www.nature.com/npjprecisiononcology/.)
  • NewsRx. U.S. Food and Drug Administration (FDA) Researchers Have Published New Data on Cancer (Augmenting precision medicine via targeted RNA-Seq detection of expressed mutations). Health & Medicine Week. July 4, 2025; p 5513.

Read more